Key terms

About PHAT

Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Florham Park, NJ.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest PHAT news

Apr 05 9:35am ET Optimistic Outlook for Phathom Pharmaceuticals’ Voquezna Despite Prescription Data Fluctuations Apr 01 6:50am ET Analysts Offer Insights on Healthcare Companies: Achieve Life Sciences (ACHV) and Phathom Pharmaceuticals (PHAT) Mar 25 7:38am ET Siga Technologies appoints Larry Miller as general counsel Mar 22 9:35am ET Positive Prescription Trends and Resilience Prompt Buy Rating for Phathom Pharmaceuticals Mar 15 10:30am ET Analysts’ Top Healthcare Picks: Longboard Pharmaceuticals (LBPH), Phathom Pharmaceuticals (PHAT) Mar 09 9:55am ET Short Report: Bearish positions reduced after contrasting C3.ai and Figs results Mar 08 8:46am ET Craig-Hallum Issues a Buy Rating on Phathom Pharmaceuticals (PHAT) Mar 08 6:27am ET Phathom Pharmaceuticals’ Voquezna Shows Promising Market Traction and Growth Potential: A Buy Rating Analysis Mar 07 5:35pm ET Maintaining Neutral on Phathom Pharmaceuticals Amid Voquezna Launch Uncertainties Mar 07 12:25pm ET Buy Rating on Phathom Pharmaceuticals Amid Strong Voquezna Launch Demand Mar 07 8:03am ET Phathom Pharmaceuticals reports Q4 EPS ($1.39), consensus ($1.08) Mar 01 9:30am ET Analysts Offer Insights on Healthcare Companies: Phathom Pharmaceuticals (PHAT) and Pacira Pharmaceuticals (PCRX) Feb 23 9:35am ET Strong Market Uptake of Phathom Pharmaceuticals’ V oquezna Spurs Buy Rating Feb 22 10:59am ET Biotech Alert: Searches spiking for these stocks today Feb 16 9:55am ET Buy Rating Justified: Voquezna’s Strong Market Launch and Growth Potential Feb 13 8:22am ET Phathom Pharmaceuticals’ VOQUEZNA Added to Express Scripts Formularies Feb 09 10:35am ET Buy Rating for Phathom Pharmaceuticals: Voquezna’s Successful Launch and Market Growth Potential Feb 02 8:50am ET Analysts Offer Insights on Healthcare Companies: Codexis (CDXS) and Phathom Pharmaceuticals (PHAT) Jan 25 8:50am ET Analysts Offer Insights on Healthcare Companies: Phathom Pharmaceuticals (PHAT) and OptimizeRx (OPRX)

No recent press releases are available for PHAT

PHAT Financials

1-year income & revenue

Key terms

PHAT Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

PHAT Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms